We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.00 | -0.13% | 1,581.50 | 1,582.50 | 1,583.50 | 1,583.00 | 1,575.50 | 1,579.50 | 59,420 | 08:10:52 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.22 | 65.15B |
From Apr 2019 to Apr 2024
LONDON--GlaxoSmithKline PLC (GSK) said it started a late-stage trial of retosiban, a drug that could potentially be used to improve the prospects for babies that are born before term.
The phase three program will seek to measure whether the treatment delays the onset of a baby's delivery and whether it improves the mortality rate. A follow-up study will assess the long-term consequences for infants.
Shares at 1110 GMT traded seven pence or 0.4% higher at 1,584 pence.
Write to Ed Ballard at ed.ballard@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
